Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
2.

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Perry CM.

Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000. Review.

PMID:
20518583
4.

Treatment of HIV infection with the CCR5 antagonist maraviroc.

Kromdijk W, Huitema AD, Mulder JW.

Expert Opin Pharmacother. 2010 May;11(7):1215-23. doi: 10.1517/14656561003801081. Review.

PMID:
20402558
5.

[Maraviroc efficacy in clinical studies on the development of the molecule].

Moreno S, Hernández B, Gutiérrez C, Delsol E.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:17-22. Review. Spanish.

PMID:
19133217
6.

CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.

Bredeek UF, Harbour MJ.

Eur J Med Res. 2007 Oct 15;12(9):427-34. Review.

PMID:
17933724
7.

Maraviroc first-line therapy for HIV infection. Too risky.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):252-4. Review.

PMID:
21284357
8.

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.

Lieberman-Blum SS, Fung HB, Bandres JC.

Clin Ther. 2008 Jul;30(7):1228-50. Review.

PMID:
18691983
9.

Clinical utility of maraviroc.

Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA.

Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Review.

PMID:
21595497
10.

When and how to use maraviroc in HIV-infected patients.

Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM.

AIDS. 2009 Nov 27;23(18):2377-85. doi: 10.1097/QAD.0b013e328332d32d. Review. No abstract available.

PMID:
19834318
11.

Maraviroc: a review of its use in HIV infection and beyond.

Woollard SM, Kanmogne GD.

Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015. Review.

12.

Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.

Yost R, Pasquale TR, Sahloff EG.

Am J Health Syst Pharm. 2009 Apr 15;66(8):715-26. doi: 10.2146/ajhp080206. Review.

PMID:
19336831
13.

Drug safety evaluation of maraviroc for the treatment of HIV infection.

Wasmuth JC, Rockstroh JK, Hardy WD.

Expert Opin Drug Saf. 2012 Jan;11(1):161-74. doi: 10.1517/14740338.2012.640670. Epub 2011 Nov 26. Review.

PMID:
22118500
14.

[Conclusions and perspectives. Maraviroc].

Alcamí J.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:49-54. Review. Spanish.

PMID:
19133222
15.

Maraviroc: a new CCR5 antagonist.

Sayana S, Khanlou H.

Expert Rev Anti Infect Ther. 2009 Feb;7(1):9-19. doi: 10.1586/14787210.7.1.9. Review.

PMID:
19622053
16.

Maraviroc.

Carter NJ, Keating GM.

Drugs. 2007;67(15):2277-88; discussion 2289-90. Review.

PMID:
17927288
17.

Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.

Caldwell DJ, Evans JD.

Expert Opin Pharmacother. 2008 Dec;9(18):3231-42. doi: 10.1517/14656560802576324 . Review.

PMID:
19040343
18.

Maraviroc, risks and benefits: a review of the clinical literature.

Emmelkamp JM, Rockstroh JK.

Expert Opin Drug Saf. 2008 Sep;7(5):559-69. doi: 10.1517/14740338.7.5.559 . Review.

PMID:
18759708
19.

Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.

Boesecke C, Pett SL.

Curr Opin HIV AIDS. 2012 Sep;7(5):456-62. doi: 10.1097/COH.0b013e328356e933. Review.

PMID:
22832708
20.

Supplemental Content

Support Center